Table 3. Lung summary table (N = 4).

Study name (year)	Study type/size	HALP threshold (method)	Outcome(s)	Summary
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival; Shen et al., (2019)	Retrospective N = 178	25.8 (X-tile)	PFS following first-line etoposide for SCLC.	In SCLC patients ≥65 years, a HALP score >25.8 was an independent predictor of improved outcome, associated with increased PFS for SCLC.
Hemoglobin, albumin, lymphocyte, and platelet score and neutrophil- to-lymphocyte ratio are novel significant prognostic factors for patients with small-cell lung cancer undergoing chemotherapy; Yang et al., (2020)	Retrospective N = 335	18.6 (X-tile)	OS in SCLC patients undergoing chemotherapy.	Low HALP (≤18.6) was an independent prognostic factor of worse OS for SCLC patients undergoing chemotherapy.
Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to- monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery; Zhai et al., (2021)	Prospective N = 238	48.0 (ROC)	OS in NSCLC after radical lung cancer surgery.	Patients with High HALP > 48.0 demonstrated superior OS to Low HALP patients in NSCLC following radical lung cancer surgery.
The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study; Wei et al., (2022)	Retrospective N = 362	48.2 (OS) 53.3 (DFS) (X-tile)	OS and DFS in NSCLC patients undergoing adjuvant chemotherapy.	Low HALP <48.2 and <53.3 predicted poorer OS (P = 0.02) and DFS (P < 0.01) outcomes respectively. Furthermore, we performed stratification analysis by tumor node metastasis (TNM) stage, and the result indicated a low HALP score predicted poor OS (P = 0.01) and DFS (P = 0.04) outcomes in stage III–IV NSCLC patients.